Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: excitatory amino acid receptor modulators - Eli Lilly

Drug Profile

Research programme: excitatory amino acid receptor modulators - Eli Lilly

Alternative Names: LY-457691; LY-458545; LY-467711; LY-525327

Latest Information Update: 27 Mar 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly; NPS Pharmaceuticals
  • Class
  • Mechanism of Action Excitatory amino acid agonists; Excitatory amino acid antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neurological disorders; Pain

Most Recent Events

  • 29 Nov 2000 The collaboration between Eli Lilly and NPS Allelix has expired, giving Eli Lilly full rights to the programme
  • 30 Dec 1998 Eli Lilly and NPS Allelix are collaborating on the development of compounds which target excitatory amino acid receptors
  • 30 Dec 1998 Preclinical development for Neurological disorders in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top